Compare Abbott Laboratories (ABT) vs SYSCO Corporation (SYY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs SYSCO Corporation — how do they compare? Abbott Laboratories trades at $95.33 (market cap $166.94B), while SYSCO Corporation trades at $83.08 (market cap $40.46B). The key difference: Abbott Laboratories is far larger — about 4.1× SYSCO Corporation's market cap, and Abbott Laboratories pays the higher dividend (2.63%). Which is the better fit depends on your goals.
| ABT | SYY | |
|---|---|---|
Market Cap | $166.94B | $40.46B |
Sector | Health | Consumer Staples |
52-Week High | $136.62 | $91.16 |
52-Week Low | $82.57 | $69.30 |
Enterprise Value | $193.69B | $53.94B |
Dividend Yield | 2.63% | 2.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Sysco (SYY) trades at $84.62, down 0.25% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported mixed Q1 2026 earnings, missing EPS estimates, but maintains steady revenue growth, reaching $81.37B in 2025. Analyst consensus is a Buy with a $83.67 price target, supported by recent corporate developments including AI awards and World Cup supply chain preparations.
Outlook remains positive due to strong institutional support and strategic initiatives, though risks include margin pressure from rising costs and high debt levels. The stock's valuation metrics like P/E of 23.4 and P/S of 0.49 suggest reasonable pricing, but investors should monitor execution on future earnings and debt management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About SYSCO Corporation
Sysco is the largest U.S. food-service distributor, boasting 17% market share of the highly fragmented food-service distribution industry. Sysco distributes over 400,000 food and nonfood products to restaurants (63% of revenue), healthcare facilities (8%), education and government buildings (8%), travel and leisure (7%), and other locations (14%) where individuals consume away-from-home meals. In fiscal 2022, 82% of the firm's revenue was U.S.-based, with 7% from Canada, 4% from the U.K., 2% from France, and 4% other.
Read more on SYY →
